Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2016 - 2021)

Summit Therapeutics filings provide 5 years of Non-Current Deffered Revenue readings, the most recent being $365000.0 for Q2 2021.

  • Quarterly Non-Current Deffered Revenue changed N/A to $365000.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $365000.0 through Jun 2021, changed N/A year-over-year, with the annual reading at $569000.0 for FY2020, 15.42% up from the prior year.
  • Non-Current Deffered Revenue hit $365000.0 in Q2 2021 for Summit Therapeutics, down from $383000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q1 2019 and bottomed at -$29.3 million in Q1 2017.
  • Average Non-Current Deffered Revenue over 4 years is -$3.7 million, with a median of $480861.1 recorded in 2019.
  • Peak annual rise in Non-Current Deffered Revenue hit 18.33% in 2020, while the deepest fall reached 18.33% in 2020.
  • Summit Therapeutics' Non-Current Deffered Revenue stood at -$29.3 million in 2017, then skyrocketed by 101.64% to $480861.1 in 2019, then rose by 18.33% to $569000.0 in 2020, then plummeted by 35.85% to $365000.0 in 2021.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Deffered Revenue are $365000.0 (Q2 2021), $383000.0 (Q1 2021), and $569000.0 (Q4 2020).